$IMUX
Immunic Inc

2017 Q4 Form 10-Q Financial Statement

#000128077617000098 Filed on October 25, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.590M $2.950M $2.770M
YoY Change 55.07% 6.5% 2.97%
% of Gross Profit
Research & Development $10.19M $9.689M $7.469M
YoY Change 15.01% 29.72% -22.57%
% of Gross Profit
Depreciation & Amortization $220.0K $216.0K $420.0K
YoY Change -46.34% -48.57% 29.23%
% of Gross Profit
Operating Expenses $14.78M $12.64M $10.24M
YoY Change 24.99% 23.44% -16.99%
Operating Profit -$12.64M -$10.24M
YoY Change 23.44% -16.99%
Interest Expense $200.0K $190.0K $80.00K
YoY Change 185.71% 137.5% 700.0%
% of Operating Profit
Other Income/Expense, Net -$10.00K $158.0K $61.00K
YoY Change -150.0% 159.02% 74.29%
Pretax Income -$14.59M -$12.48M -$10.18M
YoY Change 24.38% 22.59% -17.24%
Income Tax
% Of Pretax Income
Net Earnings -$14.59M -$12.48M -$10.18M
YoY Change 24.36% 22.63% -17.25%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$13.76M -$11.77M -$12.89M
COMMON SHARES
Basic Shares Outstanding 42.21M shares 42.21M shares 31.54M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.90M $66.40M $68.10M
YoY Change -5.17% -2.5% 13.88%
Cash & Equivalents $56.90M $66.39M $68.09M
Short-Term Investments
Other Short-Term Assets $1.200M $1.600M $1.400M
YoY Change -20.0% 14.29% -51.72%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $58.12M $67.96M $69.46M
YoY Change -5.44% -2.17% 10.95%
LONG-TERM ASSETS
Property, Plant & Equipment $2.155M $2.272M $2.922M
YoY Change -13.97% -22.25% -29.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $108.0K $126.0K $87.00K
YoY Change 86.21% 44.83% -49.12%
Total Long-Term Assets $2.263M $2.398M $3.009M
YoY Change -11.71% -20.31% -30.57%
TOTAL ASSETS
Total Short-Term Assets $58.12M $67.96M $69.46M
Total Long-Term Assets $2.263M $2.398M $3.009M
Total Assets $60.38M $70.36M $72.47M
YoY Change -5.69% -2.92% 8.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.049M $981.0K $1.193M
YoY Change 34.49% -17.77% 117.3%
Accrued Expenses $9.141M $7.167M $3.357M
YoY Change 96.33% 113.49% -54.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.28M $8.234M $4.630M
YoY Change 87.61% 77.84% -42.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $0.00 $100.0K
YoY Change 1.01% -100.0% -31.51%
Total Long-Term Liabilities $59.00K $46.00K $83.00K
YoY Change -41.0% -44.58% -43.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.28M $8.234M $4.630M
Total Long-Term Liabilities $59.00K $46.00K $83.00K
Total Liabilities $10.34M $8.280M $4.713M
YoY Change 85.3% 75.68% -42.98%
SHAREHOLDERS EQUITY
Retained Earnings -$296.0M -$281.4M -$232.1M
YoY Change 21.38% 21.23% 20.26%
Common Stock $4.000K $4.000K $3.000K
YoY Change 33.33% 33.33% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.34M $62.08M $67.76M
YoY Change
Total Liabilities & Shareholders Equity $60.38M $70.36M $72.47M
YoY Change -5.69% -2.92% 8.26%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$14.59M -$12.48M -$10.18M
YoY Change 24.36% 22.63% -17.25%
Depreciation, Depletion And Amortization $220.0K $216.0K $420.0K
YoY Change -46.34% -48.57% 29.23%
Cash From Operating Activities -$9.920M -$9.420M -$7.890M
YoY Change 9.01% 19.39% -34.47%
INVESTING ACTIVITIES
Capital Expenditures -$120.0K -$160.0K -$270.0K
YoY Change 0.0% -40.74% -12.9%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $220.0K
YoY Change -100.0% -100.0% -35.29%
Cash From Investing Activities -$110.0K -$170.0K -$50.00K
YoY Change 10.0% 240.0% -225.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 540.0K -180.0K 2.430M
YoY Change -50.91% -107.41% -1378.95%
NET CHANGE
Cash From Operating Activities -9.920M -9.420M -7.890M
Cash From Investing Activities -110.0K -170.0K -50.00K
Cash From Financing Activities 540.0K -180.0K 2.430M
Net Change In Cash -9.490M -9.770M -5.510M
YoY Change 17.16% 77.31% -54.8%
FREE CASH FLOW
Cash From Operating Activities -$9.920M -$9.420M -$7.890M
Capital Expenditures -$120.0K -$160.0K -$270.0K
Free Cash Flow -$9.800M -$9.260M -$7.620M
YoY Change 9.13% 21.52% -35.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42207376 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
dei Trading Symbol
TradingSymbol
VTL
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
780000 USD
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
981000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4656000 USD
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7167000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9601000 USD
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10353000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000 USD
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
88000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
302185000 USD
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
343351000 USD
CY2016Q4 us-gaap Assets
Assets
64026000 USD
CY2017Q3 us-gaap Assets
Assets
70358000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
61463000 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
67960000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
92000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83416000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68088000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59991000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66391000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15328000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6400000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-78000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-11000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
144000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
125000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-515000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
86000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
437000 USD
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
240620 shares
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6700590 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32143475 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42207376 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32143475 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42207376 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
4000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
574000 USD
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10178000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29235000 USD
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12483000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37485000 USD
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
44000 USD
CY2017Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
86000 USD
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
99000 USD
CY2017Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
46000 USD
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
420000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1404000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1400000 USD
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
216000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
780000 USD
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-2000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
0 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2154000 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2381000 USD
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2770000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8257000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2950000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8724000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-120000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
211000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1890000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2512000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
79000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
214000 USD
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
187000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
453000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64026000 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70358000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5480000 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8234000 USD
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
100000 USD
CY2017Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
46000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11266000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37444000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
80000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-567000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26672000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-30477000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-10178000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29235000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12481000 USD
us-gaap Net Income Loss
NetIncomeLoss
-37490000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
61000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
206000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
158000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
385000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
10239000 USD
us-gaap Operating Expenses
OperatingExpenses
29441000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
12639000 USD
us-gaap Operating Expenses
OperatingExpenses
37875000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10239000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29441000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12639000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-37875000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2784000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1051000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
434000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
387000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
467000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
222000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
223000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
208000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
655000 USD
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
253000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
736000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000 USD
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
230000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
58000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126000 USD
CY2016Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2017Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4000 USD
CY2016Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2017Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44000 USD
CY2017Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
86000 USD
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-68000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
15000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1472000 USD
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1569000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11249000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37529000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
7000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12106000 USD
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12625000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2505000 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2272000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7469000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21184000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9689000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29151000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243825000 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-281365000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3391000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3643000 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3437892 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
150493 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1382327 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.29
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4564825 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4841274 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6071707 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.78
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.76
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4430789 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5946803 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.80
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.43
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.24
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1933842 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y1M24D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1401 shares
CY2015Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
58446000 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
62078000 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31645838 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31153801 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42207376 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39054978 shares
CY2016Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
2316000 USD
CY2017Q3 vtl Accrued Clinical Costs
AccruedClinicalCosts
4556000 USD
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
23000 USD
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
0 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
25000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
10000 USD
CY2017Q3 vtl Issuance Of Securities Authorized Offering Amount
IssuanceOfSecuritiesAuthorizedOfferingAmount
113100000 USD
CY2015Q2 vtl Issuance Of Securities Authorized Offering Amount
IssuanceOfSecuritiesAuthorizedOfferingAmount
200000000 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued By Certain Stockholders Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedByCertainStockholdersUnderShelfRegistrationStatement
2500000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-17-000098-index-headers.html Edgar Link pending
0001280776-17-000098-index.html Edgar Link pending
0001280776-17-000098.txt Edgar Link pending
0001280776-17-000098-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-093017xexhibit1019.htm Edgar Link pending
vtl-093017xexhibit1020.htm Edgar Link pending
vtl-093017xexhibit311.htm Edgar Link pending
vtl-093017xexhibit312.htm Edgar Link pending
vtl-093017xexhibit321.htm Edgar Link pending
vtl-093017xexhibit322.htm Edgar Link pending
vtl-20170930.xml Edgar Link completed
vtl-20170930.xsd Edgar Link pending
vtl-20170930_cal.xml Edgar Link unprocessable
vtl-20170930_def.xml Edgar Link unprocessable
vtl-20170930_lab.xml Edgar Link unprocessable
vtl-20170930_pre.xml Edgar Link unprocessable
vtl-93017x10q.htm Edgar Link pending